Health AI Central
Share:
Peer-Reviewed Publication
Eur J Surg Oncol2026;52(2):111336.February 1, 2026Published Erratum

Corrigendum to "Dual-energy CT radiomics for predicting neoadjuvant chemotherapy response in locally advanced gastric cancer: A dual-vendor validation study" [Eur. J. Surg. Oncol. 51 (2025) 110548].

Jing Li1, Xiaoxiao Lin1, Hongkun Yin2, Tianxia Bei1, Xiaoqiang Yao1, Xuejun Chen1, Shuning Xu3, Yi Wang4, Jinrong Qu5
1Department of Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China; HNHC Key Laboratory of Oncology Medical Imaging Response Assessment, Henan Cancer Hospital, Zhengzhou, 450008, Henan, China.
2Infervision Medical Technology Co., Ltd., Beijing, 100025, China.
3Department of Gastrointestinal Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China.
4Department of Pathology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China.
5Department of Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China; HNHC Key Laboratory of Oncology Medical Imaging Response Assessment, Henan Cancer Hospital, Zhengzhou, 450008, Henan, China. Electronic address: qjryq@126.com.
PubMed DOI

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.